139 related articles for article (PubMed ID: 31231805)
1. Allergic contact dermatitis caused by paromomycin.
Veraldi S; Benzecry V; Faraci AG; Nazzaro G
Contact Dermatitis; 2019 Nov; 81(5):393-394. PubMed ID: 31231805
[No Abstract] [Full Text] [Related]
2. Occlusive paromomycin for cutaneous leishmaniasis.
Bell SA; Schaller M; Röcken M
Lancet; 1997 Jan; 349(9044):29. PubMed ID: 8988124
[No Abstract] [Full Text] [Related]
3. Occlusive paromomycin for cutaneous leishmaniasis.
Bryceson AD
Lancet; 1997 May; 349(9063):1477. PubMed ID: 9164342
[No Abstract] [Full Text] [Related]
4. [Successful topical treatment of chronic cutaneous leishmaniasis with paromomycin sulfate (15%) and methylbenzethonium chloride (12%)].
Schallreuter KU; Lemke KR
Hautarzt; 1994 Nov; 45(11):783-6. PubMed ID: 7822205
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of a combination of paromomycin and miltefosine for two vs. three courses in patients with post-kala-azar dermal leishmaniasis: an observational pilot study.
Pandey K; Pal B; Das VNR; Murti K; Lal CS; Verma N; Bimal S; Ali V; Verma RB; Topno RK; Siddiqi NA; Das P
Br J Dermatol; 2017 Aug; 177(2):557-559. PubMed ID: 27781268
[No Abstract] [Full Text] [Related]
6. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: results of a double-blind, randomized trial in Isfahan, Iran.
Iraji F; Sadeghinia A
Ann Trop Med Parasitol; 2005 Jan; 99(1):3-9. PubMed ID: 15701249
[TBL] [Abstract][Full Text] [Related]
7. [Effect of a hydrophilic formulation of topical paromomycin on cutaneous leishmaniasis among patients with contraindications for treatment with pentavalent antimonials].
Santos AM; Noronha EF; Ferreira LA; Carranza-Tamayo CO; Cupolillo E; Romero GA
Rev Soc Bras Med Trop; 2008; 41(5):444-8. PubMed ID: 19009183
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate.
Soto J; Hernandez N; Mejia H; Grogl M; Berman J
Clin Infect Dis; 1995 Jan; 20(1):47-51. PubMed ID: 7727669
[TBL] [Abstract][Full Text] [Related]
9. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.
Arana BA; Mendoza CE; Rizzo NR; Kroeger A
Am J Trop Med Hyg; 2001 Nov; 65(5):466-70. PubMed ID: 11716099
[TBL] [Abstract][Full Text] [Related]
10. Fluconazole for the treatment of cutaneous leishmaniasis.
Zvulunov A; Klaus S; Vardy D
N Engl J Med; 2002 Aug; 347(5):370-1; author reply 370-1. PubMed ID: 12151480
[No Abstract] [Full Text] [Related]
11. Non-ulcerative cutaneous leishmaniasis in Honduras fails to respond to topical paromomycin.
Neva FA; Ponce C; Ponce E; Kreutzer R; Modabber F; Olliaro P
Trans R Soc Trop Med Hyg; 1997; 91(4):473-5. PubMed ID: 9373659
[TBL] [Abstract][Full Text] [Related]
12. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
[TBL] [Abstract][Full Text] [Related]
13. Topical paromomycin for New World cutaneous leishmaniasis.
Sosa N; Pascale JM; Jiménez AI; Norwood JA; Kreishman-Detrick M; Weina PJ; Lawrence K; McCarthy WF; Adams RC; Scott C; Ransom J; Tang D; Grogl M
PLoS Negl Trop Dis; 2019 May; 13(5):e0007253. PubMed ID: 31048871
[TBL] [Abstract][Full Text] [Related]
14. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi Z; Nakhli A; Rassaii S
Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
[No Abstract] [Full Text] [Related]
15. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
Krause G; Kroeger A
Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
[No Abstract] [Full Text] [Related]
16. Treatment of cutaneous leishmaniasis with 20% paromomycin ointment.
Stanimirović A; Stipić T; Skerlev M; Basta-Juzbasić A
J Eur Acad Dermatol Venereol; 1999 Nov; 13(3):214-7. PubMed ID: 10642059
[TBL] [Abstract][Full Text] [Related]
17. [Topical treatment of persistent cutaneous leishmaniasis with paromomycin].
Flaig MJ; Rupec J; Ruzicka T; Rupec RA
Hautarzt; 2007 Aug; 58(8):689-90, 692. PubMed ID: 17676349
[TBL] [Abstract][Full Text] [Related]
18. Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate.
Faghihi G; Tavakoli-kia R
Clin Exp Dermatol; 2003 Jan; 28(1):13-6. PubMed ID: 12558620
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy for visceral leishmaniasis.
van Griensven J; Boelaert M
Lancet; 2011 Feb; 377(9764):443-4. PubMed ID: 21255829
[No Abstract] [Full Text] [Related]
20. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study.
Soto J; Fuya P; Herrera R; Berman J
Clin Infect Dis; 1998 Jan; 26(1):56-8. PubMed ID: 9455509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]